WO2019222800A1 - Procédés pour le traitement ou la prévention de maladies auto-immunes ou auto-inflammatoires - Google Patents
Procédés pour le traitement ou la prévention de maladies auto-immunes ou auto-inflammatoires Download PDFInfo
- Publication number
- WO2019222800A1 WO2019222800A1 PCT/AU2019/050492 AU2019050492W WO2019222800A1 WO 2019222800 A1 WO2019222800 A1 WO 2019222800A1 AU 2019050492 W AU2019050492 W AU 2019050492W WO 2019222800 A1 WO2019222800 A1 WO 2019222800A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- gap junction
- individual
- lupus erythematosus
- autoimmune
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 94
- 208000011594 Autoinflammatory disease Diseases 0.000 title claims abstract description 48
- 230000001363 autoimmune Effects 0.000 title claims abstract description 44
- 208000037979 autoimmune inflammatory disease Diseases 0.000 title claims abstract description 42
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 230000002265 prevention Effects 0.000 title abstract description 10
- 108050001175 Connexin Proteins 0.000 claims abstract description 173
- 102000010970 Connexin Human genes 0.000 claims abstract description 171
- 210000003976 gap junction Anatomy 0.000 claims abstract description 112
- 239000000203 mixture Substances 0.000 claims abstract description 97
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 88
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 32
- 239000003112 inhibitor Substances 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 104
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 claims description 73
- 208000024891 symptom Diseases 0.000 claims description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 27
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 23
- 229940045109 genistein Drugs 0.000 claims description 23
- 235000006539 genistein Nutrition 0.000 claims description 23
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 23
- 229960000530 carbenoxolone Drugs 0.000 claims description 22
- 210000002865 immune cell Anatomy 0.000 claims description 22
- 238000012546 transfer Methods 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 210000001616 monocyte Anatomy 0.000 claims description 19
- 239000003085 diluting agent Substances 0.000 claims description 18
- 150000003384 small molecules Chemical class 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 14
- 210000002919 epithelial cell Anatomy 0.000 claims description 14
- 229940122194 Gap junction inhibitor Drugs 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 208000010201 Exanthema Diseases 0.000 claims description 9
- 206010003246 arthritis Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 201000005884 exanthem Diseases 0.000 claims description 9
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 9
- 206010037844 rash Diseases 0.000 claims description 9
- 208000006820 Arthralgia Diseases 0.000 claims description 8
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 210000002510 keratinocyte Anatomy 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 231100000046 skin rash Toxicity 0.000 claims description 8
- 206010037660 Pyrexia Diseases 0.000 claims description 7
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 claims description 6
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 6
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 6
- 206010016256 fatigue Diseases 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 6
- 230000036211 photosensitivity Effects 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 229960000948 quinine Drugs 0.000 claims description 6
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims description 5
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 5
- 206010023232 Joint swelling Diseases 0.000 claims description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 229960003720 enoxolone Drugs 0.000 claims description 5
- XLIIRNOPGJTBJD-ROUUACIJSA-N n-[(3s,4s)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-chloro-4-fluorobenzamide Chemical compound N([C@@H]1[C@H](O)C(C)(C)OC2=CC=C(C=C21)C(=O)C)C(=O)C1=CC=C(F)C(Cl)=C1 XLIIRNOPGJTBJD-ROUUACIJSA-N 0.000 claims description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 229940013798 meclofenamate Drugs 0.000 claims description 4
- 229960001962 mefloquine Drugs 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 231100000862 numbness Toxicity 0.000 claims description 4
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 claims description 4
- 208000035824 paresthesia Diseases 0.000 claims description 4
- 229960001404 quinidine Drugs 0.000 claims description 4
- 229950009080 tonabersat Drugs 0.000 claims description 4
- SXRAPDIXXYFGJG-MDAHIHQXSA-N (2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybut Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 SXRAPDIXXYFGJG-MDAHIHQXSA-N 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 208000004044 Hypesthesia Diseases 0.000 claims description 3
- 238000002679 ablation Methods 0.000 claims description 3
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 claims description 3
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 claims description 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 3
- 208000034783 hypoesthesia Diseases 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 2
- 230000003281 allosteric effect Effects 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 210000002449 bone cell Anatomy 0.000 claims description 2
- 210000003321 cartilage cell Anatomy 0.000 claims description 2
- 229960004369 flufenamic acid Drugs 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 claims description 2
- 229960003803 meclofenamic acid Drugs 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 229960000916 niflumic acid Drugs 0.000 claims description 2
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- 210000005167 vascular cell Anatomy 0.000 claims description 2
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 claims 2
- IEAKEKFIXUZWEH-PKMKMBMKSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s,3s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-5-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]he Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 IEAKEKFIXUZWEH-PKMKMBMKSA-N 0.000 claims 1
- IMPQXXMPTCAGJB-YOCMHDSMSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O.C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O IMPQXXMPTCAGJB-YOCMHDSMSA-N 0.000 claims 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 38
- 108030002637 Cyclic GMP-AMP synthases Proteins 0.000 description 38
- 238000009472 formulation Methods 0.000 description 38
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 32
- 239000000463 material Substances 0.000 description 26
- 239000004480 active ingredient Substances 0.000 description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- -1 dihydrochloride Chemical compound 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- OBZHEBDUNPOCJG-WBXJDKIVSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-WBXJDKIVSA-N 0.000 description 21
- 239000003995 emulsifying agent Substances 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000003755 preservative agent Substances 0.000 description 20
- 208000023275 Autoimmune disease Diseases 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 17
- 239000000796 flavoring agent Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 14
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000003765 sweetening agent Substances 0.000 description 14
- 230000005353 IP-10 production Effects 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 239000000375 suspending agent Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 10
- 239000007859 condensation product Substances 0.000 description 10
- 235000013355 food flavoring agent Nutrition 0.000 description 10
- 235000003599 food sweetener Nutrition 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 10
- 230000000069 prophylactic effect Effects 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 108091006146 Channels Proteins 0.000 description 9
- 239000004150 EU approved colour Substances 0.000 description 9
- 239000001828 Gelatine Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000003086 colorant Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 229920000159 gelatin Polymers 0.000 description 9
- 235000019322 gelatine Nutrition 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 8
- 239000004166 Lanolin Substances 0.000 description 8
- 239000004909 Moisturizer Substances 0.000 description 8
- 239000007900 aqueous suspension Substances 0.000 description 8
- 239000003974 emollient agent Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 235000019388 lanolin Nutrition 0.000 description 8
- 229940039717 lanolin Drugs 0.000 description 8
- 239000002480 mineral oil Substances 0.000 description 8
- 230000001333 moisturizer Effects 0.000 description 8
- 239000004006 olive oil Substances 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 229960004063 propylene glycol Drugs 0.000 description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000000080 wetting agent Substances 0.000 description 8
- 241000157855 Cinchona Species 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000002270 dispersing agent Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 235000008390 olive oil Nutrition 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 239000012049 topical pharmaceutical composition Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 108010069241 Connexin 43 Proteins 0.000 description 6
- 102000001045 Connexin 43 Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 229940057995 liquid paraffin Drugs 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 244000105624 Arachis hypogaea Species 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000000585 Mann–Whitney U test Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229920001615 Tragacanth Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical class OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 4
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 235000006491 Acacia senegal Nutrition 0.000 description 4
- 235000003911 Arachis Nutrition 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000008228 bacteriostatic water for injection Substances 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 102100037156 Gap junction beta-2 protein Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- XEEQGYMUWCZPDN-UHFFFAOYSA-N [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol Chemical compound C=1C(C(F)(F)F)=NC2=C(C(F)(F)F)C=CC=C2C=1C(O)C1CCCCN1 XEEQGYMUWCZPDN-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- 235000013928 guanylic acid Nutrition 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 230000035992 intercellular communication Effects 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 208000018937 joint inflammation Diseases 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000009038 pharmacological inhibition Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001185 psoriatic effect Effects 0.000 description 3
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000004034 viscosity adjusting agent Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- JSOVGYMVTPPEND-UHFFFAOYSA-N 16-methylheptadecyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)(C)C JSOVGYMVTPPEND-UHFFFAOYSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
- AMRBZKOCOOPYNY-QXMHVHEDSA-N 2-[dimethyl-[(z)-octadec-9-enyl]azaniumyl]acetate Chemical compound CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O AMRBZKOCOOPYNY-QXMHVHEDSA-N 0.000 description 2
- CETWDUZRCINIHU-UHFFFAOYSA-N 2-heptanol Chemical compound CCCCCC(C)O CETWDUZRCINIHU-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- YVBCULSIZWMTFY-UHFFFAOYSA-N 4-Heptanol Natural products CCCC(O)CCC YVBCULSIZWMTFY-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000021513 Cinchona Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 2
- 208000035690 Familial cold urticaria Diseases 0.000 description 2
- 102100039290 Gap junction gamma-1 protein Human genes 0.000 description 2
- 241000208680 Hamamelis mollis Species 0.000 description 2
- RZKSECIXORKHQS-UHFFFAOYSA-N Heptan-3-ol Chemical compound CCCCC(O)CC RZKSECIXORKHQS-UHFFFAOYSA-N 0.000 description 2
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 208000006802 Lupus erythematosus panniculitis Diseases 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 235000019169 all-trans-retinol Nutrition 0.000 description 2
- 239000011717 all-trans-retinol Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940073669 ceteareth 20 Drugs 0.000 description 2
- 229940073642 ceteareth-30 Drugs 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 210000001513 elbow Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 229940074045 glyceryl distearate Drugs 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- RCLXAPJEFHPYEG-ZWKOTPCHSA-N n-[(3r,4s)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide Chemical compound N([C@@H]1[C@@H](O)C(C)(C)OC2=CC=C(C=C21)C(=O)C)C(=O)C1=CC=C(F)C=C1 RCLXAPJEFHPYEG-ZWKOTPCHSA-N 0.000 description 2
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 210000004049 perilymph Anatomy 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940101027 polysorbate 40 Drugs 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940012894 qualaquin Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011536 re-plating Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002210 silicon-based material Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229940118846 witch hazel Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- XGDZAPUEJRQPOD-ZLCLUPBPSA-N (5z,8z,11z,14z)-n-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO XGDZAPUEJRQPOD-ZLCLUPBPSA-N 0.000 description 1
- XHKUDCCTVQUHJQ-BILMMMPYSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-BILMMMPYSA-N 0.000 description 1
- ZHNFLHYOFXQIOW-AHSOWCEXSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-AHSOWCEXSA-N 0.000 description 1
- QPUQNFRDMXWYKM-QZOPMXJLSA-N (z)-octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O.CCCCCCCC\C=C/CCCCCCCC(N)=O QPUQNFRDMXWYKM-QZOPMXJLSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- UNOFRSFHIUMSNW-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]but-3-en-1-ol Chemical compound C=CCC(O)C1=CC=C(C(F)(F)F)C=C1 UNOFRSFHIUMSNW-UHFFFAOYSA-N 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- YIKKMWSQVKJCOP-ABXCMAEBSA-N 7-ketocholesterol Chemical compound C1C[C@H](O)CC2=CC(=O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]3[C@]21C YIKKMWSQVKJCOP-ABXCMAEBSA-N 0.000 description 1
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-KGZHIOMZSA-N 7beta-hydroxycholesterol Chemical compound C([C@@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-KGZHIOMZSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- FTQDJVZNPJRVPG-XWEVEMRCSA-N Acetoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C FTQDJVZNPJRVPG-XWEVEMRCSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000026326 Adult-onset Still disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 201000003762 Chilblain lupus Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010069156 Connexin 26 Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 244000308760 Helichrysum petiolatum Species 0.000 description 1
- 235000013537 Helichrysum petiolatum Nutrition 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 101000962345 Homo sapiens NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000020060 Increased inflammatory response Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010050551 Lupus-like syndrome Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000009777 Majeed syndrome Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101100043703 Mus musculus Sting1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 201000004854 SAPHO syndrome Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 1
- 101150060741 Sting1 gene Proteins 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960004871 acetoxolone Drugs 0.000 description 1
- FTQDJVZNPJRVPG-UHFFFAOYSA-N acetoxolone Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(OC(=O)C)C1(C)C FTQDJVZNPJRVPG-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940100609 all-trans-retinol Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229950010117 anifrolumab Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001562 benzopyrans Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229950011546 carabersat Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000002388 complement deficiency Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 108010015426 connexin 45 Proteins 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000024526 cutaneous mucinosis Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 206010018797 guttate psoriasis Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 201000010241 mucinoses Diseases 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- LMGPCDPXTYKGLM-UHFFFAOYSA-N n-(2h-chromen-2-yl)benzamide Chemical class O1C2=CC=CC=C2C=CC1NC(=O)C1=CC=CC=C1 LMGPCDPXTYKGLM-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 206010057887 neonatal lupus erythematosus Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229940113162 oleylamide Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000025487 periodic fever syndrome Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000030683 polygenic disease Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to compositions and methods for the treatment or prevention of autoimmune or autoinflammatory diseases.
- autoinflammation The ability to distinguish foreign microorganisms from host cells is crucial to avoid detrimental localised damage to self during an inflammatory response.
- immune cells begin to target and damage host cells and tissues.
- adaptive cells break self-tolerance, the resulting condition is characterised as autoimmunity, where native host cells are recognised as foreign and the adaptive immune cells target them for destruction.
- autoinflammation When innate immune cells become activated, due to dysregulated secretion of pro-inflammatory cytokines and consequent damage to host tissues, it is termed autoinflammation
- Autoimmune diseases cause significant human morbidity and mortality. These diseases include approximately 80 diseases, such as rheumatoid arthritis, systemic lupus and multiple sclerosis, and affect approximately 5% of the population of the United States. Dysregulation of the immune system plays a critical underpinning role in conditions such as autoimmune diseases.
- Autoinflammatory diseases are a group of clinical conditions other than autoimmune diseases, characterized by recurrent inflammatory episodes. From a pathogenetic point of view they are determined by a dysregulation of innate immunity, without involvement of specific immunity (auto reactive T cells and auto antibodies).
- a key element of the innate immune system is the cGAS/STING pathway responsible for sensing cytosolic DNA. Activation of the cGAS/STING pathway leads to the rapid stimulation of a potent inflammatory response. This response is characterised by strong induction of type I interferons and pro-inflammatory cytokines such as IL-6, TNF-a and IFN-beta.
- the inflammatory response is characterized by increased blood flow, increased capillary permeability, and the influx of phagocytic cells. These events result in swelling, redness, warmth (altered heat patterns), and pus formation at the site of injury.
- cGAS protein cyclic GMP-AMP Synthase
- STING Stimulator of Interferon Genes
- the present invention provides a method of treating an autoimmune or autoinflammatory disease in an individual, the method comprising, consisting essentially of or consisting of inhibiting a gap junction in the individual, thereby treating the autoimmune or autoinflammatory disease.
- the autoimmune or autoinflammatory disease may be any one described herein.
- the autoimmune disease is selected from the group consisting of lupus, arthritis and psoriasis.
- the autoimmune disease is systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).
- SLE systemic lupus erythematosus
- CLE cutaneous lupus erythematosus
- the methods, uses or compositions of the invention find utility in treating or minimising the severity of a flare-up of the symptoms of SLE or of CLE.
- the flare-up may be induced following exposure to sunlight.
- the present invention provides a method of treating lupus erythematosus in an individual, the method comprising, consisting essentially of or consisting of inhibiting a gap junction in the individual, thereby treating lupus erythematosus in the subject.
- the method includes administering a gap junction inhibitor to the individual.
- the lupus erythematosus is cutaneous lupus erythematosus.
- the lupus erythematosus is systemic lupus erythematosus (SLE).
- the present invention thus also provides a method of treating or preventing, or reducing the severity of a sunlight-induced flare up of the symptoms of lupus erythematosus in an individual, the method comprising, consisting essentially of or consisting of inhibiting a gap junction in an individual who has been diagnosed with lupus erythematosus and is at risk of a sunlight-induced flare up of symptoms, thereby treating or preventing a sunlight-induced flare up of the symptoms of lupus erythematosus in the individual.
- the symptom of lupus erythematosus is preferably selected from: joint pain, joint swelling, weakness, fatigue, tingling, numbness, skin rash.
- the lupus erythematosus is cutaneous lupus erythematosus.
- the lupus erythematosus is systemic lupus erythematosus (SLE).
- SLE systemic lupus erythematosus
- the present invention also provides a method of treating photosensitivity in an individual diagnosed with or suspected of having lupus erythematosus, the method comprising, consisting essentially of or consisting of inhibiting a gap junction in an individual who has been diagnosed with lupus erythematosus, thereby treating photosensitivity in the individual.
- inhibiting a gap junction may be by administration of a small molecule, an antibody, a peptide, a protein, an antisense oligonucleotide or an interfering RNA to the individual.
- the inhibitor is a small molecule.
- Inhibition may be by genetic ablation of all or part of the gene encoding one or more gap junction proteins (e.g. connexins), introduction of an inactivating mutation of a gene encoding one or more gap junction proteins, inactivation of a regulator of gap junction gene transcription, inactivation of a regulator of gap junction mRNA translation or inactivation of an allosteric potentiator of gap junction activity. Any molecule that results in this inhibition is an inhibitor of a gap junction.
- inhibiting a gap junction may be by inhibiting one or more gap junction proteins. Typically, this involves administering an inhibitor of one of more gap junction proteins to an individual. Preferably, an inhibitor of one or more gap junction proteins inhibits the capacity of the gap junction proteins to form a functional intercellular channel.
- a functional intercellular channel is one that allows direct diffusion of ions or small molecules between adjacent cells.
- the adjacent cells are a non-immune cell and an immune cell. Examples of non-immune cells are an epithelial cell, a keratinocyte, a vascular cell, a neuron or a bone/cartilage cell.
- the non-immune cell is an epithelial cell, a keratinocyte, or a neuron, more preferably an epithelial cell.
- the immune cell is a monocyte.
- the gap junction protein may be a connexin.
- the inhibitor of one or more gap junction proteins directly inhibits the interaction between one connexin with another connexin, for example the inhibitor may prevent the formation of a homo- or heterohexameric connexon or hemichannel.
- the inhibitor may inhibit the association between hemichannels on adjacent cells thereby inhibiting, preventing or reducing formation of a functional intercellular channel.
- the inhibitor may inhibit, prevent or reduce the formation of, or level of, polymorphic maculae or plaques containing clusters of gap junctions.
- the inhibitor of one or more gap junction proteins inhibits the capacity of the gap junction to form a functional intercellular channel thereby inhibiting, preventing or reducing the transfer of cyclic guanosine monophosphate- adenosine monophosphate (herein referred to as either cyclic GMP-AMP or cGAMP), or other bacterial-derived cyclic di-nucleotides (e.g. cyclic dimeric adenosine monophosphate, or cyclic dimeric guanosine monophosphate) from one cell to another cell.
- the inhibitor binds to a site on a connexin that is involved in interaction with another connexin.
- the inhibitor may bind to one or both of the two extracellular loops of the connexin protein.
- peptide inhibitors are Gap26 and Gap27, which are identical to amino acid sequences on the first and second extracellular loop regions of connexin 43, respectively. Peptides that are identical to the first and second extracellular loop regions of the other connexins are also contemplated for use in the invention.
- the inhibitor is selective and binds to 1 , 2 or 3 different connexins.
- the inhibitor is non-selective and binds to greater than 3 different connexins.
- the inhibitor may be any one described herein, including in Table 1.
- the inhibitor of a gap junction may exhibit a K ⁇ value of less than 1 mM, preferably less than 100pM, less than 10mM, less than 1 mM, less than 100nM, less than 50nM, less than 40nM, less than 10nM as determined by an assay as described herein.
- the inhibitor of a gap junction may exhibit an ICso of less than 1 mM, preferably less than 100pM, less than 10pM, less than 1 pM, less than 100nM, less than 90nM, less than 80nM, less than 50nM, less than 40nM, less than 10nM as determined by an assay as described herein.
- the invention also provides a method of alleviating or ameliorating a symptom of an autoimmune or autoinflammatory disease in an individual in need thereof, the method comprising, consisting essentially of or consisting of administering to the individual in need thereof a therapeutically effective amount of an inhibitor of a gap junction, thereby alleviating or ameliorating a symptom of an autoimmune or autoinflammatory disease in the individual.
- the symptom of an autoimmune or autoinflammatory disease which is alleviated or ameliorated according to the present invention is a symptom of lupus erythematosus.
- the symptom of lupus erythematosus is a symptom of cutaneous lupus erythematosus (CLE).
- the symptoms of lupus erythematosus is a symptom of systemic lupus erythematosus (SLE).
- the symptom of SLE or of CLE is a symptom that is induced or occurs after exposure of the individual to sunlight or UV radiation.
- the present invention provides a method for the treatment of an autoimmune or autoinflammatory disease in an individual comprising, consisting essentially of or consisting of the steps of identifying a subject having an autoimmune or autoinflammatory disease; and administering to the individual in need thereof a therapeutically effective amount of an inhibitor of a gap junction, thereby treating the autoimmune or autoinflammatory disease in the individual.
- the invention provides a method for the treatment of lupus erythematosus in an individual comprising, consisting essentially of or consisting of the steps of: identifying a subject having lupus erythematosus; and administering to the individual in need thereof a therapeutically effective amount of an inhibitor of a gap junction, thereby treating the lupus erythematosus in the individual.
- the invention provides a method for the prevention or reduction of the severity of a flare-up of symptoms of lupus erythematosus in an individual comprising, consisting essentially of or consisting of the steps of identifying a subject having lupus erythematosus wherein the individual is at risk of prolonged exposure to sunlight; and administering to the individual in need thereof a therapeutically effective amount of an inhibitor of a gap junction, thereby preventing a flare-up of symptoms of lupus erythematosus in the individual.
- the present invention also provides a method for inhibiting or minimising the progression of a flare-up of symptoms of lupus erythematosus in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of an inhibitor of a gap junction to an individual who is experiencing a flare-up of symptoms of lupus erythematosus thereby inhibiting or minimising the progression of a flare-up of symptoms of lupus erythematosus in the individual.
- the method further comprises the step of providing or identifying an individual who is experiencing a flare-up of symptoms of lupus erythematosus.
- An individual may be identified as experiencing a flare-up of symptoms of lupus erythematosus by any biochemical or clinical method or test as described herein.
- the present invention also provides use of an inhibitor of a gap junction in the manufacture of a medicament for:
- the present invention also provides use of an inhibitor of a gap junction in the manufacture of a medicament for treating lupus erythematosus in an individual.
- the present invention also provides an inhibitor of a gap junction for use in treating an autoimmune or autoinflammatory disease in an individual. More particularly, the present invention also provides an inhibitor of a gap junction for use in:
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising, consisting essentially of, or consisting of an inhibitor of a gap junction and a pharmaceutically acceptable carrier, diluent or excipient for use in treating an autoimmune or autoinflammatory disease in an individual.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising, consisting essentially of, or consisting of an inhibitor of a gap junction and a pharmaceutically acceptable carrier, diluent or excipient for use in treating lupus erythematosus in an individual, or for use in preventing a flare up of symptoms of lupus erythematosus in an individual exposed or at risk of exposure to sunlight.
- the invention provides a pharmaceutical composition for treating an autoimmune or autoinflammatory disease, preferably lupus erythematosus comprising an inhibitor of a gap junction and a pharmaceutically acceptable diluent, excipient or carrier.
- the only active ingredient present in the composition is an inhibitor of a gap junction.
- the invention provides a pharmaceutical composition for treating an autoimmune or autoinflammatory disease, preferably lupus erythematosus comprising as an active ingredient an inhibitor of an autoimmune or autoinflammatory disease and a pharmaceutically acceptable diluent, excipient or carrier.
- an autoimmune or autoinflammatory disease preferably lupus erythematosus
- a pharmaceutically acceptable diluent, excipient or carrier preferably a pharmaceutically acceptable diluent, excipient or carrier.
- the only active ingredient present in the composition is an inhibitor of a gap junction.
- the invention provides a pharmaceutical composition for treating an autoimmune or autoinflammatory disease, preferably lupus erythematosus comprising as a main ingredient an inhibitor of a gap junction and a pharmaceutically acceptable diluent, excipient or carrier.
- an autoimmune or autoinflammatory disease preferably lupus erythematosus
- a pharmaceutically acceptable diluent, excipient or carrier preferably a pharmaceutically acceptable diluent, excipient or carrier.
- the only active ingredient present in the composition is an inhibitor of a gap junction.
- an inhibitor of a gap junction may be administered system ically or directly to the site of disease.
- the inhibitor of a gap junction may be formulated for oral administration.
- the inhibitor of a gap junction may be formulated for topical administration, for example in the context of treating or treating or preventing symptoms of a sunlight-induced flare up of cutaneous lupus erythematosus.
- the present invention also provides a kit for use, or when used, in a method of the invention, the kit comprising, consisting essentially of or consisting of:
- FIG. 1 Gap junctions facilitate amplification of cGAMP signal by monocytes a- c) PMA-activated THP-1 (WT, cGASKO or STINGKO) (a, b) or primary monocytes (c) were co-cultured for 24 h with HEK293T WT or cGAS overexpressing (producing constitutive levels of cGAMP). Supernatants were collected and IP-10 levels analysed by ELISA. Carbenoxolone (CBX) at 100 mM was used to assess the impact of gap junction inhibition on the activation of IFN-I response by HEK cGAS (c). IP-10 was not detected in HEK WT or cGAS.
- CBX Carbenoxolone
- FIG. 2 Connexin expression in epithelial cells and monocytic cells is required for cGAMP transfer a) PMA-activated THP-1 cGAS-KO cells were co-cultured for 24 h with HEK293T WT or HEK293T lacking CX43/45, previously transfected with vectors encoding GFP or cGAS for 2 h (leading to cGAMP production). Supernatants were collected and IP-10 levels analysed by ELISA.
- THP-1 WT cells were pre-treated or not with PMA for 2 h, prior to co- culture for 24 h with HEK cGAS high cells, or direct stimulation with transfected cGAS (ISD 70) or STING (cGAMP) agonists. Supernatants were collected and IP 10 levels analysed by ELISA.
- THP-1 WT cells were pre-treated with 20 ng/ml PMA for indicated amount of time prior to lysis and western blot analysis of CX43 protein levels. CX43 levels were increased with time of treatment with PMA. All data shown are representative of a minimum of 2 independent experiments.
- FIG. 3 cGAMP transfer from HaCaT cells to monocytes after UV stimulation a) PMA differentiated WT THP-1 cells were co-cultured 24 h with HaCaT (WT, cGASKO or STINGKO) pre-treated with UV (7.5mJ/cm 2 ). IP10 were measured in supernatants by ELISA b) HEK293T (WT or cGAS overexpressing - producing constitutive levels of cGAMP) were co-cultured with HaCaT cells for 24 h, and IL-6 measured in supernatants by ELISA.
- IL-6 production confirms by-stander response to cGAMP in HaCaT cells - validating that HaCaT cGASKO are responsive to cGAMP.
- HaCaT cells did not make detectable IP 10 (not shown).
- Data shown is averaged of at least 2 independent experiments ( ⁇ sem). *p ⁇ 0.05.
- FIG. 4 cGAMP produced by joint fibroblast-like synoviocytes can transfer to activate STING in adjacent monocytes through gap junctions, resulting in positive feedback increasing further joint inflammation
- FLS primary Fibroblast-Like Synoviocytes
- ISD lipofectamine only
- Genistein inhibits cGAMP-mediated transactivation through its effect on connexins in either cGAMP donor or recipient cells a) HEK wild type or expressing low level of cGAS (cGAS l0W - making constitutive levels of cGAMP) were treated for 48 h with 30 or 50 mM Genistein for 48 h prior to being co-cultured (after replating the cells at similar densities for each condition) with mouse L929 cells expressing an Interferon Stimulated Responsive Element (ISRE)-Luciferase reporter (referred to as “LL171 cells”).
- ISRE Interferon Stimulated Responsive Element
- Data are averaged from 3 independent experiments in biological triplicate ( ⁇ s.e.m and unpaired Mann-Whitney U- tests shown) d) HEK expressing Sting and an IFN-beta Luciferase reporter and lacking connexin 43/45 (CXKO) or not (CXWT) were treated for 8 h with 50 mM Genistein prior rinsing and overnight co-culture with FIEK cGAS l0W . Data shown is averaged from 2 independent experiments in biological triplicate ( ⁇ s.e.m and unpaired Mann-Whitney U- tests shown).
- IFN-I receptor IFNAR
- anifrolumab IFN-I receptor
- aspects of the invention of inhibiting gap junctions allow retention of the capacity to sense pathogens and trigger an immune response, while also retaining the capacity to activate senescence in epithelial cells.
- An advantage of the aspects of the present invention is that only the positive feedback loop operated by the cell:cell communication of cGAMP, which favours autoimmunity or autoinflammation, is targeted.
- a“gap junction inhibitor” or“inhibitor of a gap junction” is any compound or molecule that inhibits, reduces or prevents the formation of a functional intercellular channel between adjacent cells. This may be by inhibiting the formation of a connexin in a cell, or inhibiting the interaction between connexins on adjacent cells. Inhibition, reduction or prevention of formation of a function intercellular channel between adjacent cells leads to a reduction in the direct diffusion of ions or small molecules, for example cGAMP, between adjacent cells. Inhibiting a gap junction may be by inhibiting one or more gap junction proteins. Preferably, an inhibitor of one or more gap junction proteins inhibits the capacity of the gap junction proteins to form a functional intercellular channel.
- a functional intercellular channel is one that allows direct diffusion of ions or small molecules between adjacent cells.
- the inhibitor of one or more gap junction proteins directly inhibits the interaction between one connexin with another connexin, for example the inhibitor may prevent the formation of a homo- or heterohexameric connexin or hemichannel.
- the compound may inhibit the interaction between two of the same connexins, e.g. inhibit the interaction between one Gx43 protein with another Gx43 protein, or may inhibit the interaction between two different connexins, e.g. inhibit the interaction between one Gx43 protein with Gx45 protein.
- the inhibitor may inhibit, prevent or reduce the formation of, or level of, polymorphic maculae or plaques containing clusters of gap junctions.
- the gap junction inhibitor may be an indirect inhibitor, for example, by acting directly on an agent which itself reduces expression or activity of a gap junction protein.
- an indirect inhibitor is Genistein, which is known to activate PKC and MAPK, and which in turn are thought to inactivate gap junctions via promoting the phosphorylation of connexins including Cx43.
- Non-limiting examples of compounds that may be a“gap junction inhibitor” or “inhibitor of a gap junction” include a small molecule, an antibody, a peptide, a protein, an antisense oligonucleotide, an interfering RNA or a synthetic oligonucleotide (e.g. antisense or aptamer).
- the inhibitor binds to a site on a connexin that is involved in interaction with another connexin.
- the inhibitor may bind to one or both of the two extracellular loops of the connexin protein.
- Examples of peptide inhibitors are Gap26 and Gap27, which are identical to amino acid sequences on the first and second extracellular loop regions of connexin 43, respectively. Peptides that are identical to the first and second extracellular loop regions of the other connexins are also contemplated for use in the invention.
- the inhibitor is selective and binds to 1 , 2 or 3 different connexins.
- the inhibitor is non-selective and binds to greater than 3 different connexins.
- the capacity for a compound to inhibit a gap junction may be measured by any method or assay described herein.
- small molecule denotes a generally low molecular weight compound and includes organic and inorganic compounds.
- a small molecule has a well- defined chemical formula with a single molecular weight.
- a small molecule has a molecular weight of less than 3000 daltons. More preferably, a small molecule has a molecular weight of less than 2000 daltons. In some embodiments of this invention, the small molecule has a molecular weight of less than 1000 daltons.
- Some non-limiting examples of small molecules include lipids such as fatty acids; saccharides (mono, di or poly); xenobiotics; organometallic compounds and natural products.
- An antibody inhibitor of a gap junction protein can be produced via techniques known in the art to generate an antibody against gap junction protein and then those antibodies can be screened for inhibitory activity using assays as described herein.
- monoclonal antibodies can be prepared as follows. Immunization of mice or other appropriate host animal by a connexin or fragment thereof. Immunization with a connexin or fragment thereof and/or adjuvant may be by multi-point injection usually subcutaneous injection or intraperitoneal injection. A connexin or fragment thereof may be conjugated to a carrier, such as serum albumin, or soybean trypsin on inhibitor, an antigen to enhance immunogenicity in the host.
- the preferred animal system for generating hybridomas is the murine system.
- Fusion cell partners e.g., murine myeloma cell lines SP2/0, NS0, NS1 , rat myeloma Y3, rabbit myeloma 240E 1 , human K6H6
- fusion and screening procedures are also well known in the art.
- the present invention also includes the use of functional analogs, variants and derivatives of the above-mentioned gap junction inhibitors.
- the present invention contemplates the use of Glycyrrhetinic acid and functional derivatives or analogues thereof.
- Glycyrrhetinic acid (CAS no 471 -53-4, also known as Enoxolone or glycyrrhetic acid) is a pentacyclic triterpenoid derivative of the beta-amyrin type obtained from the hydrolysis of glycyrrhizic acid, which was obtained from the herb liquorice.
- Carbenoxolone (CBX, CAS no: 5697-56-3) is a glycyrrhetinic acid derivative with a steroid-like structure, similar to substances found in the root of the licorice plant. Carbenoxolone reversibly inhibits the conversion of inactive cortisone to cortisol by blocking 11 b-hydroxysteroid dehydrogenase (I ⁇ b-HSD). I ⁇ b-HSD also reversibly catalyzes the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. Carbenoxolone is a modestly potent, reasonably effective, water-soluble blocker of gap junctions. Carbenoxolone is available as a topical cream such as Carbosan gel.
- Glycyrrhetinic acid is Acetoxolone.
- Retinoic acid ((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1 - yl)nona-2,4,6,8-tetraenoic acid, CAS no 302-79-4) is a metabolite of vitamin A1 (all- trans-retinol) that mediates the functions of vitamin A1 required for growth and development. Isomers include 13-cis- and 9-cis-retinoic acid. Other retinoid medications include Tretinoin and Isotretinoin.
- the present invention also contemplates the use of quinine and functional analogs and derivatives thereof obtained from the cinchona tree.
- Quinine (sold as Qualaquin, Quinate, Quinbisul, and others, CAS no: 130-95-0) is an alkaloid derived from the bark of the cinchona tree. Quinine is a basic amine and is usually provided as a salt. Various existing preparations include the hydrochloride, dihydrochloride, sulfate, bisulfate and gluconate. In the United States, quinine sulfate is commercially available in 324-mg tablets under the brand name Qualaquin. All quinine salts may be given orally or intravenously (IV); quinine gluconate may also be given intramuscularly (IM) or rectally (PR).
- IV intravenously
- quinine gluconate may also be given intramuscularly (IM) or rectally (PR).
- Quinidine (CAS no 56-54-2) is a stereoisomer of quinine, and is sold under the trade names Quinaglute, Quinidex. Quinidine acts as a blocker of voltage-gated sodium channels. Inhibition of the Nav1.5 channel is specifically involved in its antiarrhythmic effects as a class I antiarrhythmic agent. Quinidine also blocks certain voltage-gated potassium channels (e.g., Kv1.4, Kv4.2, hERG, among others), acts as an antimuscarinic and alpha-1 blocker, and is an antimalarial (as is quinine).
- voltage-gated potassium channels e.g., Kv1.4, Kv4.2, hERG, among others
- Mefloquine (sold under the brand names Lariam Mephaquin, Mefliam, others, CAS no: 53230-10-7).
- Melfoquine is also known as [(R*,S*)-2,8- bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol and alpha-2-Piperidinyl-2,8- bis(trifluoromethyl)-4-quinolinemethanol. It is available in tablets of 228mg base (250mg salt).
- Anandamide (CAS no 94421 -68-8, also known as N-arachidonoylethanolamine or AEA), is a fatty acid neurotransmitter derived from the non-oxidative metabolism of eicosatetraenoic acid (arachidonic acid), an essential w-6 polyunsaturated fatty acid.
- Anandamide is also known as (5Z,8Z,11 Z, 14Z)-N-(2-hydroxyethyl)icosa-5, 8,11 ,14- tetraenamide).
- Oleamide (CAS no: 301 -02-0, also known as (Z)-Octadec-9-enamide, Oleylamide, and Cis-9,10-octadecenoamide) is the amide derived from the fatty acid oleic acid.
- the gap junction inhibitor is a member of the anthranilic acid derivatives class of NSAID drugs which include: meclofenamic acid (also known as meclofenamate sodium, brand Meclomen, CAS no 644-62-2), mefenamic acid, flufenamic acid (CAS no 530-78-9) and Niflumic acid (CAS no 4394- 00-7).
- meclofenamic acid also known as meclofenamate sodium, brand Meclomen, CAS no 644-62-2
- mefenamic acid also known as meclofenamate sodium, brand Meclomen, CAS no 644-62-2
- mefenamic acid also known as meclofenamate sodium, brand Meclomen, CAS no 644-62-2
- mefenamic acid also known as meclofenamate sodium, brand Meclomen, CAS no 644-62-2
- mefenamic acid also known as meclofenamate sodium, brand Meclomen, CAS no 644-62-2
- mefenamic acid
- 1 -Heptanol (CAS no 111 -70-6) is an alcohol with a seven carbon chain and the structural formula of CH3(CH2)60H. It is a clear colorless liquid that is very slightly soluble in water, but miscible with ether and ethanol. There are three other isomers of heptanol that have a straight chain, 2-heptanol, 3-heptanol, and 4-heptanol, which differ by the location of the alcohol functional group.
- Octanol (111 -87-5) is another alcohol that can be used to inhibit connexins in accordance with the present invention.
- Tonabersat SB-220405 is a benzopyran derivative that blocks the cortical spreading depression proposed to be associated with migraine attacks. Tonabersat is a member of a family of novel benzoylamino-benzopyran compounds, typified by carabersat (SB-204269),
- the inhibitor of a gap junction or of a gap junction protein is Genistein, or a functional analog or derivative thereof.
- Genistein is an isoflavone, also known as 5,7-Dihydroxy-3-(4-hydroxyphenyl)chromen-4-one or 4', 5, 7- Trihydroxyisoflavone (CAS no 446-72-0).
- Genistein has previously been implicated as a negative mediator of proliferation and angiogenesis in vitro, partially by down-regulating cell adhesion-related genes and impairing cell adhesions.
- Genistein acts to inhibit gap junctions is surprising given the previous reports that flavonoids increase expression of connexins including Cx 43.
- the present inventors are the first to demonstrate that Genistein acts differently to other isoflavonoid molecules, and inhibits the transfer of cGAMP between cells.
- the ability for Genistein to inhibit the transfer of cGAMP between cells was shown to be dependent upon connexins 43 and 45.
- the inventors have demonstrated that Genistein inhibits cGAMP-mediated transactivation through its effect on connexins.
- gap junction mimetic peptides which can be used to inhibit connexins are described, for example, in WO/2006/134494.
- the inhibitor of a gap junction may inhibit the function of the intercellular channel at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or preferably by up to 100%.
- the inhibitor inhibits the transfer of cGAMP, c-di- AMP, or c-di-GMP to an immune cell by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or preferably by up to 100%.
- the inhibitor of a gap junction may exhibit a K ⁇ value of less than 1 mM, preferably less than 100pM, less than 10mM, less than 1 mM, less than 100nM, less than 50nM, less than 40nM, less than 10nM.
- the K ⁇ is a measure of the transfer of cGAMP, c-di-AMP, or c-di-GMP to an immune cell, typically from an epithelial cell, using an assay or a method as described herein.
- the inhibitor of a gap junction may exhibit an IC50 of less than 1 mM, preferably less than 100pM, less than 10mM, less than 1 mM, less than 100nM, less than 90nM, less than 80nM, less than 50nM, less than 40nM, less than 10nM.
- the IC50 is a measure of the transfer of cGAMP, c-di-AMP, or c-di-GMP to an immune cell, typically from an epithelial cell, using an assay or a method as described herein.
- Cyclic guanosine monophosphate-adenosine monophosphate (cGAMP; cyclic GMP-AMP; cGAMP(2'-5'); cyclic Gp(2'-5')Ap(3'-5')) is a cyclic di-nucleotide.
- cGAMP is synthesized by cyclic GMP-AMP synthase (cGAS) from ATP and GTP upon cytosolic DNA stimulation.
- cGAMP produced by cGAS contains mixed phosphodiester linkages, with one between 2'-OH of GMP and 5'- phosphate of AMP and the other between 3'-OH of AMP and 5'-phosphate of GMP.
- the structure of cGAMP is shown below:
- An exemplary assay to measure inhibition of gap junction intercellular communication may be any one described herein or any one described in Abacci et al. Biotechniques. 2008 Jul;45(1 ):33-52, 56-62.
- the method may be micro- injection, scrape Loading/electroporation, Gap-FRAP (Fluorescence Recovery after Photobleaching), Preloading Assay, LAMP (Local Activation of Molecular Fluorescent Probe), Radiolabeled Nucleotides Transfer, Intercellular Calcium Waves (ICW), Dual Whole-cell Patch Clamp.
- LAMP Local Activation of Molecular Fluorescent Probe
- Radiolabeled Nucleotides Transfer e.g. small molecule, peptide, antibody, RNAi or other molecule
- a compound e.g. small molecule, peptide, antibody, RNAi or other molecule, can inhibit, prevent or reduce gap junction mediated intercellular communication.
- autoinflammation When adaptive cells break self-tolerance, the resulting condition is characterised as autoimmunity, where native host cells are recognised as foreign and the adaptive immune cells target them for destruction.
- autoimmunity When innate immune cells become activated, due to dysregulated secretion of pro-inflammatory cytokines and consequent damage to host tissues, it is termed autoinflammation.
- autoimmune disease refers generally to those diseases characterized by the failure of one or more B- and/or T-cell populations, or gene products thereof, to distinguish between self and non-self antigenic determinants.
- autoinflammatory disease or“autoinflammatory diseases” (AIDs) refers generally to those diseases characterized by the dysregulated secretion of pro-inflammatory cytokines and consequent damage to host tissues.
- AIDs and systemic autoimmune diseases share some characteristics: they start with the prefix "auto" to define a pathological process directed against self; they are systemic diseases, frequently involving musculoskeletal system; both include monogenic and polygenic diseases. From the pathogenetic point of view, they are characterized by a chronic activation of immune system, which eventually leads to tissue inflammation in genetically predisposed individuals. Nevertheless, the specific effectors of the damage are different in the two groups of diseases: in AIDs the innate immune system directly causes tissue inflammation, whereas in ADs the innate immune system activates the adaptive immune system which, in turn, is responsible for the inflammatory process.
- Some conditions may be characterized as exhibiting both autoimmune and autoinflammatory features.
- autoimmune diseases are often characterized by the infiltration of the target cells with inflammatory lymphoid cells, for example, mononuclear phagocytes, lymphocytes and plasma cells as well as secondary lymphoid follicles.
- autoimmune diseases or disorders include, but are not limited to, inflammatory responses such as inflammatory skin diseases including psoriasis and dermatitis (e.g., atopic dermatitis); systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); respiratory distress syndrome (including adult respiratory distress syndrome; ARDS); dermatitis; meningitis; encephalitis; uveitis; colitis; glomerulonephritis; allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythe
- Both monogenic autoinflammatory diseases and multifactorial autoinflam matory diseases are contemplated. Examples of both are described in Ciccarelli et al. Curr Med Chem. 2013 Jan; 21 (3): 261-269, such as Familial Mediterranean Fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), Flyperimmuno globulinemia W with periodic fever syndrome (H IDS), Cryopyrin associated periodic syndrome (CAPS), Familial cold auto inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), Neonatal onset multisystemic inflammatory disorder (NOMID), NALP12-associated periodic fever, Deficit of IL-1 receptor antagonist (DIRA), Majeed’s syndrome, Pyogenic arthritis pyoderma gangrenosum and acne syndrome (PAPA), Blau’s syndrome, Periodic fever, aphthous stomatitis, pharyngitis and adenopathy syndrome (PFAPA), Behcet’s Disease, Chron’s Disease, Still’s Disease, Adult-onset Still Disease,
- therapeutically effective amount generally refers to an amount of one or more inhibitors, or, if a small molecule inhibitor, a pharmaceutically acceptable salt, polymorph or prodrug thereof of the present invention that (i) treats the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
- preventing or “prevention” is intended to refer to at least the reduction of likelihood of the risk of (or susceptibility to) acquiring a disease or disorder (i.e. , causing at least one of the clinical symptoms of the disease not to develop in a individual that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).
- Biological and physiological parameters for identifying such patients are provided herein and are also well known by physicians.
- the methods of the present invention can be to prevent or reduce the severity, or inhibit or minimise progression, of a flare-up or symptom of a disease or condition as described herein.
- the methods of the present invention have utility as treatments as well as prophylaxes.
- treatment or “treating” of a subject includes the inhibition of a gap junction in an individual with the purpose of delaying, slowing, stabilizing, curing, healing, alleviating, relieving, altering, remedying, less worsening, ameliorating, improving, or affecting the disease or condition, the symptom of the disease or condition, or the risk of (or susceptibility to) the disease or condition.
- treating refers to any indication of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; lessening of the rate of worsening; lessening severity of the disease; stabilization, diminishing of symptoms or making the injury, pathology or condition more tolerable to the individual; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a subject's physical or mental well-being.
- a “subject” herein is preferably human subject. Although the invention finds application in humans, the invention is also useful for veterinary purposes. The invention is useful for domestic or farm animals such as cattle, sheep, horses and poultry; for companion animals such as cats and dogs; and for zoo animals. It will be understood that the terms“subject” and“individual” are interchangeable in relation to an individual requiring treatment according to the present invention.
- the therapeutically effective amount of a compound corresponds to preferably between about 0.01 to about 10% (w/w), or between about 0.1 to 10% (w/w), or between about 1.0 to about 10% (w/w), between about 0.1 to about 5% (w/w), or between about 1.0 to about 5% (w/w).
- the therapeutically effective amount of a compound corresponds preferably between about 1 to about 50 mg/kg, or between about 1 to 25 mg/kg, or between about 1 to about 10 mg/kg, between about 5 to about 25 mg/kg, or between about 10 to about 20 mg/kg.
- the proportion of the inhibitor described herein may be at least about 0.5%, 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the total active present in the composition, typically stored in solution for a suitable period of time under suitable conditions.
- Suitable periods of time and conditions include ranges of time and conditions under which a skilled practitioner might reasonably expect to keep a inhibitor in solution prior to use. For example, periods of time of about 24 hours, about 48 hours, or about 72 hours are typical, although some solutions may be kept for longer periods for example, at least a week, a month, 6 months, 1 year, 2 years, 3 years or more.
- Storage conditions may typically be room temperature and relative humidity, or typically 25° C. and 60% relative humidity, but could include any standard storage conditions encountered by the skilled person, for example approximately 4° C., -20° C., or -80° C.
- the frequency of administration may be once daily, or 2 or 3 time daily.
- the treatment period may be for the duration of the detectable disease.
- a therapeutically effective dosage is formulated to contain a concentration (by weight) of at least about 0.1 % up to about 50% or more, and all combinations and sub-combinations of ranges therein.
- the compositions can be formulated to contain one or more the inhibitors described herein in a concentration of from about 0.1 to less than about 50%, for example, about 49, 48, 47, 46, 45, 44, 43, 42, 41 or 40%, with concentrations of from greater than about 0.1 %, for example, about 0.2, 0.3, 0.4 or 0.5%, to less than about 40%, for example, about 39, 38, 37, 36, 35, 34, 33, 32, 31 or 30%.
- compositions may contain from about 0.5% to less than about 30%, for example, about 29, 28, 27, 26, 25, 25, 24, 23, 22, 21 or 20%, with concentrations of from greater than about 0.5%, for example, about 0.6, 0.7, 0.8, 0.9 or 1 %, to less than about 20%, for example, about 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10%.
- the compositions can contain from greater than about 1 % for example, about 2%, to less than about 10%, for example about 9 or 8%, including concentrations of greater than about 2%, for example, about 3 or 4%, to less than about 8%, for example, about 7 or 6%.
- the active agent can, for example, be present in a concentration of about 5%. In all cases, amounts may be adjusted to compensate for differences in amounts of active ingredients actually delivered to the treated cells or tissue.
- the autoimmune diseases are selected from the group consisting of lupus, arthritis and psoriasis.
- SLE Systemic lupus erythematosus
- SLE is a multi-system autoimmune disease. At least 5 million people worldwide have SLE; 90% of those diagnosed are female and most develop the disease between the ages of 15-44. In Australia, SLE is diagnosed in ⁇ 1 in 1000 people and is more prevalent and severe in Native Australians and Asian Australians. SLE patients suffer chronic immune-mediated inflammatory damage in the brain, kidneys, heart, lungs, joints, skin, and other organs, resulting in a marked loss of life expectancy, exemplified by a standardized mortality ratio above 3. In a British cohort, the average age of death of the 14% of patients who died during follow-up was only 52 years. Most often the clinical course is characterised by episodic flares, which are associated with accrual of irreversible organ damage and thereby mortality.
- lupus include discoid, drug-induced and neonatal lupus.
- systemic lupus erythematosus also known as SLE
- SLE systemic lupus erythematosus
- a more thorough categorization of lupus includes the following types: acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, discoid lupus erythematosus (chronic cutaneous), childhood discoid lupus erythematosus, generalized discoid lupus erythematosus, localized discoid lupus erythematosus, chilblain lupus erythematosus (Hutchinson), lupus erythematosus-lichen planus overlap syndrome, lupus erythematosus panniculitis (lupus erythematosus profundus),
- Cutaneous lupus erythematosus (CLE) is seen in the majority of SLE cases and is most often observed in skin exposed to the sun, appearing as a variety of severe and in some cases disfiguring skin rashes. Lupus may also manifest as a purely cutaneous form, also known as incomplete lupus erythematosus. While all the factors leading to the development of SLE, and its pattern of intermittent flares, are not known, it is clear that sunlight exposure is important in systemic as well as cutaneous disease exacerbation.
- Inhibition of sunlight driven flares by gap junction inhibition has the potential to stop disease progression and increase life expectancy. Successful treatment may be determined by a decreased in the severity or frequency of flares and an increase in survival time.
- the present invention includes methods of preventing sunlight- induced symptoms of SLE and CLE such as joint pains, weakness, fatigue, fever, skin rashes, tingling, and numbness in an individual diagnosed with or suspected of having lupus.
- the methods of the present invention find utility in preventing or reducing the severity of a UV- or sunlight-exposure induced flare-up of the symptoms of SLE.
- administration of a gap junction inhibitor either before a period of sunlight-exposure, or alternatively, in the period following sunlight-exposure may be used to inhibit the progression of the cGAMP-mediated inflammatory process leading to expression or exacerbation of symptoms of lupus erythematosus in an individual.
- the methods of the invention can be used to prevent or reduce the severity of a flare-up of the symptoms of SLE and/or CLE.
- Psoriasis is an inflammatory skin condition relating to the hyper-proliferation of keratinocytes which affects ⁇ 2% of the general population, and involving T lymphocytes.
- Skin lesions are chronic red plaques often observed on elbows, knees, scalp, and umbilicus/lumbar areas. Eruptive guttate psoriasis is often the initial manifestation triggered by with a streptococcal infection.
- Psoriatic lesions can progress to erythroderma impacting the entire body surface. It may also associate with join inflammation. There is evidence that psoriatic lesions contain keratinocytes with increased connexin expression - with example of CX26.
- Successful treatment may be determined by a decrease of inflammatory plaques for a period of time (the duration of remission is a measure of treatment).
- RA Rheumatoid arthritis
- Sjogren Sjogren syndrome
- RA directly impacts the working life of patients, with 60% being unable to work 10 years after onset of their disease. RA also impacts life expectancy by 3-7 years for females/males. There is evidence that increased gap junction intercellular communication mediated by Cx43 contributes to the development of RA, and that this could result to increased levels of joint pro-inflammatory cytokines such as TNFa.
- Successful treatment may be determined by a decrease in joint inflammation, bone destruction, pain and increased life expectancy.
- compositions comprising, formulations and modes of administration
- compositions of the invention typically include a therapeutically effective amount of an inhibitor of one or more in admixture with one or more pharmaceutically and physiologically acceptable formulation materials.
- suitable formulation materials include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants.
- a suitable vehicle may be water for injection, physiological saline solution, or artificial perilymph, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles.
- compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- a pharmaceutically acceptable carrier includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.
- materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminium hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as
- Various dosage units are each preferably provided as a discrete dosage tablet, capsules, lozenge, dragee, gum, or other type of solid formulation.
- Capsules may encapsulate a powder, liquid, or gel.
- the solid formulation may be swallowed, or may be of a suckable or chewable type (either frangible or gum-like).
- the present invention contemplates dosage unit retaining devices other than blister packs; for example, packages such as bottles, tubes, canisters, packets.
- the dosage units may further include conventional excipients well-known in pharmaceutical formulation practice, such as binding agents, gellants, fillers, tableting lubricants, disintegrants, surfactants, and colorants; and for suckable or chewable formulations.
- compositions intended for oral use may further comprise one or more components such as sweetening agents, flavouring agents, colouring agents and/or preserving agents in order to provide appealing and palatable preparations.
- Tablets contain the active ingredient in admixture with physiologically acceptable excipients that are suitable for the manufacture of tablets.
- excipients include, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents such as corn starch or alginic acid, binding agents such as starch, gelatine or acacia, and lubricating agents such as magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatine capsules wherein the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium such as peanut oil, liquid paraffin or olive oil.
- an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin
- an oil medium such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active ingredient(s) in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients include suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as naturally-occurring phosphatides (for example, lecithin), condensation products of an alkylene oxide with fatty acids such as polyoxyethylene stearate, condensation products of ethylene oxide with long chain aliphatic alcohols such as heptadecaethyleneoxycetanol, condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono-oleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides such as polyethylene sorbitan monooleate.
- Aqueous suspensions may also comprise one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- colouring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavouring agents such as sucrose or saccharin.
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and/or flavouring agents may be added to provide palatable oral preparations.
- Such suspensions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
- compositions may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil such as olive oil or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof.
- Suitable emulsifying agents include naturally- occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides such as sorbitan monoleate, and condensation products of partial esters derived from fatty acids and hexitol with ethylene oxide such as polyoxyethylene sorbitan monoleate.
- An emulsion may also comprise one or more sweetening and/or flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also comprise one or more demulcents, preservatives, flavouring agents and/or colouring agents.
- Compositions or particles of the invention may be formulated for local or topical administration, such as for topical application to the skin. Formulations for topical administration typically comprise a topical vehicle combined with active agent(s), with or without additional optional components.
- Topical vehicles include organic solvents such as alcohols (for example, ethanol, iso-propyl alcohol or glycerine), glycols such as butylene, isoprene or propylene glycol, aliphatic alcohols such as lanolin, mixtures of water and organic solvents and mixtures of organic solvents such as alcohol and glycerine, lipid- based materials such as fatty acids, acylglycerols including oils such as mineral oil, and fats of natural or synthetic origin, phosphoglycerides, sphingolipids and waxes, protein- based materials such as collagen and gelatine, silicone-based materials (both nonvolatile and volatile), and hydrocarbon-based materials such as microsponges and polymer matrices.
- organic solvents such as alcohols (for example, ethanol, iso-propyl alcohol or glycerine), glycols such as butylene, isoprene or propylene glycol, aliphatic alcohols such as lanolin, mixture
- a composition may further include one or more components adapted to improve the stability or effectiveness of the applied formulation, such as stabilizing agents, suspending agents, emulsifying agents, viscosity adjusters, gelling agents, preservatives, antioxidants, skin penetration enhancers, moisturizers and sustained release materials.
- stabilizing agents such as hydroxymethylcellulose or gelatine-microcapsules, liposomes, albumin microspheres, microemulsions, nanoparticles or nanocapsules.
- a topical formulation may be prepared in a variety of physical forms including, for example, solids, pastes, creams, foams, lotions, gels, powders, aqueous liquids, emulsions, sprays and skin patches.
- the physical appearance and viscosity of such forms can be governed by the presence and amount of emulsifier(s) and viscosity adjuster(s) present in the formulation.
- Solids are generally firm and non-pourable and commonly are formulated as bars or sticks, or in particulate form.
- Solids can be opaque or transparent, and optionally can contain solvents, emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product.
- Creams and lotions are often similar to one another, differing mainly in their viscosity. Both lotions and creams may be opaque, translucent or clear and often contain emulsifiers, solvents, and viscosity adjusting agents, as well as moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product.
- Gels can be prepared with a range of viscosities, from thick or high viscosity to thin or low viscosity. These formulations, like those of lotions and creams, may also contain solvents, emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product. Liquids are thinner than creams, lotions, or gels, and often do not contain emulsifiers. Liquid topical products often contain solvents, emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product.
- Emulsifiers for use in topical formulations include, but are not limited to, ionic emulsifiers, cetearyl alcohol, non-ionic emulsifiers like polyoxyethylene oleyl ether, PEG-40 stearate, ceteareth-12, ceteareth-20, ceteareth-30, ceteareth alcohol, PEG-100 stearate and glyceryl stearate.
- Suitable viscosity adjusting agents include, but are not limited to, protective colloids or nonionic gums such as hydroxyethylcellulose, xanthan gum, magnesium aluminum silicate, silica, microcrystalline wax, beeswax, paraffin, and cetyl palmitate.
- a gel composition may be formed by the addition of a gelling agent such as chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyquaterniums, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbomer or ammoniated glycyrrhizinate.
- a gelling agent such as chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyquaterniums, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbomer or ammoniated glycyrrhizinate.
- Suitable surfactants include, but are not limited to, nonionic, amphoteric, ionic and anionic surfactants.
- dimethicone copolyol polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, lauramide DEA, cocamide DEA, and cocamide MEA, oleyl betaine, cocam idopropyl phosphatidyl PG-dimonium chloride, and ammonium laureth sulfate may be used within topical formulations.
- Preservatives include, but are not limited to, antimicrobials such as methylparaben, propylparaben, sorbic acid, benzoic acid, and formaldehyde, as well as physical stabilizers and antioxidants such as vitamin E, sodium ascorbate/ascorbic acid and propyl gallate.
- Suitable moisturizers include, but are not limited to, lactic acid and other hydroxy acids and their salts, glycerine, propylene glycol, and butylene glycol.
- Suitable emollients include lanolin alcohol, lanolin, lanolin derivatives, cholesterol, petrolatum, isostearyl neopentanoate and mineral oils.
- Suitable fragrances and colours include, but are not limited to, FD&C Red No. 40 and FD&C Yellow No. 5.
- Other suitable additional ingredients that may be included in a topical formulation include, but are not limited to, abrasives, absorbents, anticaking agents, antifoaming agents, antistatic agents, astringents (such as witch hazel), alcohol and herbal extracts such as chamomile extract, binders/excipients, buffering agents, chelating agents, film forming agents, conditioning agents, propellants, opacifying agents, pH adjusters and protectants.
- Typical modes of delivery for topical compositions include application using the fingers, application using a physical applicator such as a cloth, tissue, swab, stick or brush, spraying including mist, aerosol or foam spraying, dropper application, sprinkling, soaking, and rinsing.
- Controlled release vehicles can also be used, and compositions may be formulated for transdermal administration (for example, as a transdermal patch).
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3- butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- the oral compositions can also include adjuvant
- compositions and particles of the invention may be administered orally, nasally, intravenously, intramuscularly, ocularly, transdermally, intraperitoneally, or subcutaneously.
- the particles of the invention are administered intravenously.
- injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
- Suitable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono-or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- the effective amounts and method of administration of the present invention for modulation of an immune response can vary based on the individual, what condition is to be treated and other factors evident to one skilled in the art. Factors to be considered include route of administration and the number of doses to be administered.
- compositions may be formulated as sustained release formulations such as a capsule that creates a slow release of modulator following administration.
- sustained release formulations such as a capsule that creates a slow release of modulator following administration.
- Such formulations may generally be prepared using well-known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site.
- Carriers for use within such formulations are biocompatible, and may also be biodegradable.
- the formulation provides a relatively constant level of modulator release.
- the amount of modulator contained within a sustained release formulation depends upon, for example, the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.
- kit or article of manufacture including one or more compositions, peptides and/or pharmaceutical compositions as described above.
- kit for use in a therapeutic or prophylactic application mentioned above including:
- the kit may contain one or more further active principles or ingredients for treatment of an autoimmune disease, particularly a demyelination disorder such as multiple sclerosis.
- the kit or“article of manufacture” may comprise a container and a label or package insert on or associated with the container.
- Suitable containers include, for example, bottles, vials, syringes, blister pack, etc.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a therapeutic composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- the label or package insert indicates that the therapeutic composition is used for treating the condition of choice.
- the label or package insert includes instructions for use and indicates that the therapeutic or prophylactic composition can be used to treat an inflammatory disease or condition described herein.
- the kit may comprise (a) a therapeutic or prophylactic composition; and (b) a second container with a second active principle or ingredient contained therein.
- the kit in this embodiment of the invention may further comprise a package insert indicating the composition and other active principle can be used to treat a disorder or prevent a complication stemming from an autoimmune disease described herein.
- the kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
- BWFI bacteriostatic water for injection
- the therapeutic composition may be provided in the form of a device, disposable or reusable, including a receptacle for holding the therapeutic, prophylactic or pharmaceutical composition.
- the device is a syringe.
- the device may hold 1 -2 ml_ of the therapeutic composition.
- the therapeutic or prophylactic composition may be provided in the device in a state that is ready for use or in a state requiring mixing or addition of further components.
- compositions of the invention typically include a therapeutically effective amount of an inhibitor of a gap junction in admixture with one or more pharmaceutically and physiologically acceptable formulation materials.
- suitable formulation materials include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants.
- a suitable vehicle may be water for injection, physiological saline solution, or artificial perilymph, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles.
- the primary solvent in a vehicle may be either aqueous or non-aqueous in nature.
- the vehicle may contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation.
- the vehicle may contain still other pharmaceutically-acceptable excipients for modifying or maintaining the rate of release of an inhibitor of a gap junction, or for promoting the absorption or penetration of an inhibitor of a gap junction, for example, across the skin or intestinal lining.
- the therapeutic composition may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder.
- Such formulations may be stored either in a ready to use form or in a form, e.g., lyophilized, requiring reconstitution prior to administration.
- the optimal pharmaceutical formulations will be determined by one skilled in the art depending upon considerations such as the route of administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712, the disclosure of which is hereby incorporated by reference. Such formulations may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the gap junction inhibitor.
- Topical vehicles include organic solvents such as alcohols (for example, ethanol, iso-propyl alcohol or glycerine), glycols such as butylene, isoprene or propylene glycol, aliphatic alcohols such as lanolin, mixtures of water and organic solvents and mixtures of organic solvents such as alcohol and glycerine, lipid- based materials such as fatty acids, acylglycerols including oils such as mineral oil, and fats of natural or synthetic origin, phosphoglycerides, sphingolipids and waxes, protein- based materials such as collagen and gelatine, silicone-based materials (both nonvolatile and volatile), and hydrocarbon-based materials such as microsponges and polymer matrices.
- organic solvents such as alcohols (for example, ethanol, iso-propyl alcohol or glycerine), glycols such as butylene, isoprene or propylene glycol, aliphatic alcohols such as lanolin, mixture
- an inhibitor of a gap junction which is administered in this fashion may be encapsulated and may be formulated with or without those carriers customarily used in the compounding of solid dosage forms.
- the capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional excipients may be included to facilitate absorption of an inhibitor of a gap junction. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.
- compositions intended for oral use may further comprise one or more components such as sweetening agents, flavouring agents, colouring agents and/or preserving agents in order to provide appealing and palatable preparations.
- Tablets contain the active ingredient in admixture with physiologically acceptable excipients that are suitable for the manufacture of tablets.
- excipients include, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents such as corn starch or alginic acid, binding agents such as starch, gelatine or acacia, and lubricating agents such as magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatine capsules wherein the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium such as peanut oil, liquid paraffin or olive oil.
- an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin
- an oil medium such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active ingredient(s) in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients include suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as naturally-occurring phosphatides (for example, lecithin), condensation products of an alkylene oxide with fatty acids such as polyoxyethylene stearate, condensation products of ethylene oxide with long chain aliphatic alcohols such as heptadecaethyleneoxycetanol, condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono-oleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides such as polyethylene sorbitan monooleate.
- Aqueous suspensions may also comprise one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- colouring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavouring agents such as sucrose or saccharin.
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and/or flavouring agents may be added to provide palatable oral preparations.
- Such suspensions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
- compositions may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil such as olive oil or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof.
- Suitable emulsifying agents include naturally- occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides such as sorbitan monoleate, and condensation products of partial esters derived from fatty acids and hexitol with ethylene oxide such as polyoxyethylene sorbitan monoleate.
- An emulsion may also comprise one or more sweetening and/or flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also comprise one or more demulcents, preservatives, flavouring agents and/or colouring agents.
- sweetening agents such as glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also comprise one or more demulcents, preservatives, flavouring agents and/or colouring agents.
- Additional formulation components may include materials which provide for the prolonged residence of an inhibitor as described herein so as to maximize the topical contact and promote absorption. Suitable materials include polymers or gel forming materials which provide for increased viscosity of the preparation.
- the suitability of the formulations of the instant invention for controlled release (e.g., sustained and prolonged delivery) of an inhibitor as described herein can be determined by various procedures known in the art..
- the specific dose of a gap junction inhibitor may be calculated according to considerations of body weight, body surface area or organ size. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed, especially in light of the dosage information and assays disclosed herein. Appropriate dosages may be ascertained through use of the established assays for determining dosages utilized in conjunction with appropriate dose-response data.
- the final dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g., the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding the appropriate dosage levels for the treatment of various diseases and conditions.
- an inhibitor of a gap junction may be advantageous for a given treatment. While continuous administration may be accomplished via a mechanical means, such as with an infusion pump, it is contemplated that other modes of continuous or near continuous administration may be practiced. For example, chemical derivatization or encapsulation may result in sustained release forms of the inhibitor which have the effect of continuous presence, in predictable amounts, based on a determined dosage regimen.
- an inhibitor of a gap junction includes inhibitors derivatized or otherwise formulated to effectuate such continuous administration.
- a composition may further include one or more components adapted to improve the stability or effectiveness of the applied formulation, such as stabilizing agents, suspending agents, emulsifying agents, viscosity adjusters, gelling agents, preservatives, antioxidants, skin penetration enhancers, moisturizers and sustained release materials.
- stabilizing agents such as hydroxymethylcellulose or gelatine-microcapsules, liposomes, albumin microspheres, microemulsions, nanoparticles or nanocapsules.
- Emulsifiers for use in topical formulations include, but are not limited to, ionic emulsifiers, cetearyl alcohol, non-ionic emulsifiers like polyoxyethylene oleyl ether, PEG-40 stearate, ceteareth-12, ceteareth-20, ceteareth-30, ceteareth alcohol, PEG-100 stearate and glyceryl stearate.
- Suitable viscosity adjusting agents include, but are not limited to, protective colloids or nonionic gums such as hydroxyethylcellulose, xanthan gum, magnesium aluminum silicate, silica, microcrystalline wax, beeswax, paraffin, and cetyl palmitate.
- a gel composition may be formed by the addition of a gelling agent such as chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyquaterniums, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbomer or ammoniated glycyrrhizinate.
- a gelling agent such as chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyquaterniums, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbomer or ammoniated glycyrrhizinate.
- Suitable surfactants include, but are not limited to, nonionic, amphoteric, ionic and anionic surfactants.
- dimethicone copolyol polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, lauramide DEA, cocamide DEA, and cocamide MEA, oleyl betaine, cocam idopropyl phosphatidyl PG-dimonium chloride, and ammonium laureth sulfate may be used within topical formulations.
- Preservatives include, but are not limited to, antimicrobials such as methylparaben, propylparaben, sorbic acid, benzoic acid, and formaldehyde, as well as physical stabilizers and antioxidants such as vitamin E, sodium ascorbate/ascorbic acid and propyl gallate.
- Suitable moisturizers include, but are not limited to, lactic acid and other hydroxy acids and their salts, glycerine, propylene glycol, and butylene glycol.
- Suitable emollients include lanolin alcohol, lanolin, lanolin derivatives, cholesterol, petrolatum, isostearyl neopentanoate and mineral oils.
- Suitable fragrances and colours include, but are not limited to, FD&C Red No. 40 and FD&C Yellow No. 5.
- Other suitable additional ingredients that may be included in a topical formulation include, but are not limited to, abrasives, absorbents, anticaking agents, antifoaming agents, antistatic agents, astringents (such as witch hazel), alcohol and herbal extracts such as chamomile extract, binders/excipients, buffering agents, chelating agents, film forming agents, conditioning agents, propellants, opacifying agents, pH adjusters and protectants.
- Inhalant compositions may comprise liquid or powdered compositions containing the active ingredient that are suitable for nebulization and intrabronchial use, or aerosol compositions administered via an aerosol unit dispensing metered doses.
- Suitable liquid compositions comprise the active ingredient in an aqueous, pharmaceutically acceptable inhalant solvent such as isotonic saline or bacteriostatic water.
- the solutions are administered by means of a pump or squeeze-actuated nebulized spray dispenser, or by any other conventional means for causing or enabling the requisite dosage amount of the liquid composition to be inhaled into the patient's lungs.
- Suitable formulations, wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
- compositions may be formulated as sustained release formulations such as a capsule that creates a slow release of modulator following administration.
- sustained release formulations such as a capsule that creates a slow release of modulator following administration.
- Such formulations may generally be prepared using well-known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site.
- Carriers for use within such formulations are biocompatible, and may also be biodegradable.
- the formulation provides a relatively constant level of modulator release.
- the amount of modulator contained within a sustained release formulation depends upon, for example, the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.
- kit or article of manufacture including one or more inhibitors of a gap junction, as described herein, or a pharmaceutically acceptable salt, polymorph or prodrug thereof and/or pharmaceutical composition as described above.
- kits for use in a therapeutic or prophylactic application mentioned above including:
- the kit may contain one or more further active ingredients for treatment or prevention of an autoimmune or autoinflammatory disease.
- the kit or“article of manufacture” may comprise a container and a label or package insert on or associated with the container.
- Suitable containers include, for example, bottles, vials, syringes, blister pack, etc.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a therapeutic composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- the label or package insert indicates that the therapeutic composition is used for treating the condition of choice.
- the label or package insert includes instructions for use and indicates that the therapeutic or prophylactic composition can be used to treat or prevent an autoimmune or autoinflammatory disease as described herein.
- the kit may comprise (a) a therapeutic or prophylactic composition; and (b) a second container with a second active principle or ingredient contained therein.
- the kit in this embodiment of the invention may further comprise a package insert indicating the composition and other active principle can be used to treat a disorder or prevent a complication stemming from an autoimmune disease as described herein.
- the kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
- BWFI bacteriostatic water for injection
- the therapeutic composition may be provided in the form of a device, disposable or reusable, including a receptacle for holding the therapeutic, prophylactic or pharmaceutical composition.
- the device is a syringe.
- the device may hold 1 -2 ml_ of the therapeutic composition.
- the therapeutic or prophylactic composition may be provided in the device in a state that is ready for use or in a state requiring mixing or addition of further components.
- cGAMP made by an epithelial cell constitutively producing it can be transferred to co-cultured 24 h with PMA activated THP-1 monocytes, where it activates production of the cytokine IP-10 through STING, independently of cGAS ( Figure 1A).
- THP-1 cells genetically lacking cGAS were still able to respond to cGAMP producing cells, demonstrating that it is not engagement of cGAS in the THP-1 cells which is at play in the transactivation by the HEK cGAS cells.
- STING deficiency in the THP-1 cells ablated IP-10 production, in line with the direct role of cGAMP from the HEK cGAS cells in the transactivation by the HEK cGAS cells.
- THP-1 cells required a 2 h PMA pre-treatment to produce IP-10 when co-cultured with HEK cGAS high cells (Figure 2C).
- This requirement for PMA differentiation of the THP-1 cells did not relate to their basal capacity to respond to cGAS or STING, since liposome based transfection of 70 nt double stranded DNA or synthetic cGAMP activated IP-10 production in un-primed cells ( Figure 2C).
- FLSs human joint fibroblast-like synoviocytes
- ISD immunostimulatory DNA
- the experiments described in Figure 5C show that pre-treatment of human TERT immortalised BJ fibroblasts (referred to as“hTERT”) with Genistein (75 mM) for 48h reduces their capacity to transfer cGAMP to LL171 cells, after transfection of the hTERT with 1 pg/ml ISD.
- the experiments described in Figure 5D show that 8h pre-treatment of HEK expressing mouse Sting (referred to as“HEK Sting CX WT”) and an Interferon (IFN)-p- Luciferase reporter with 50 pM Genistein, inhibits their capacity to respond to cGAMP generated by co-cultured HEK cGAS l0W cells.
- HEK Sting lacking connexins 43 and 45 (referred to as“HEK Sting CX KO”), do not respond to co-cultured HEK cGAS l0W cells and are not impacted on by Genistein.
- Genistein can inhibit cGAMP-mediated transactivation, through its effect on connexins in either cGAMP donor or recipient cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions et des procédés pour le traitement ou la prévention de maladies auto-immunes ou auto-inflammatoires. Dans un aspect, la présente invention concerne un procédé de traitement d'une maladie auto-immune ou auto-inflammatoire chez un individu, le procédé comprenant, consistant essentiellement ou consistant à inhiber une jonction lacunaire chez l'individu, traitant ainsi la maladie auto-immune ou auto-inflammatoire. De préférence, la maladie auto-immune ou auto-inflammatoire est le lupus érythémateux.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018901775 | 2018-05-21 | ||
AU2018901775A AU2018901775A0 (en) | 2018-05-21 | Method of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019222800A1 true WO2019222800A1 (fr) | 2019-11-28 |
Family
ID=68615505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2019/050492 WO2019222800A1 (fr) | 2018-05-21 | 2019-05-21 | Procédés pour le traitement ou la prévention de maladies auto-immunes ou auto-inflammatoires |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019222800A1 (fr) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003238441A (ja) * | 2002-02-08 | 2003-08-27 | 英行 ▲高▼野 | 血管新生抑制剤 |
WO2006134494A2 (fr) * | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Composes anti-connexine et leurs utilisations |
WO2009114097A2 (fr) * | 2008-03-03 | 2009-09-17 | Fabio Grassi | Procédé de modulation de réponses immunitaires dépendantes des cellules t |
WO2009147442A1 (fr) * | 2008-06-05 | 2009-12-10 | Minster Research Limited | Nouveaux traitements |
WO2012020021A1 (fr) * | 2010-08-10 | 2012-02-16 | Onepharm Research & Development Gmbh | Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques |
US20150238548A1 (en) * | 2014-02-21 | 2015-08-27 | Genmont Biotech Incorporation | Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases |
CN107050011A (zh) * | 2017-04-28 | 2017-08-18 | 灏ゅ己 | 染料木素在制备抗自身免疫性肝炎药物中的应用 |
WO2017147561A1 (fr) * | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | Anticorps se liant aux hémicanaux de la connexine (cx) 43 et leurs utilisations |
-
2019
- 2019-05-21 WO PCT/AU2019/050492 patent/WO2019222800A1/fr active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003238441A (ja) * | 2002-02-08 | 2003-08-27 | 英行 ▲高▼野 | 血管新生抑制剤 |
WO2006134494A2 (fr) * | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Composes anti-connexine et leurs utilisations |
WO2009114097A2 (fr) * | 2008-03-03 | 2009-09-17 | Fabio Grassi | Procédé de modulation de réponses immunitaires dépendantes des cellules t |
WO2009147442A1 (fr) * | 2008-06-05 | 2009-12-10 | Minster Research Limited | Nouveaux traitements |
WO2012020021A1 (fr) * | 2010-08-10 | 2012-02-16 | Onepharm Research & Development Gmbh | Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques |
US20150238548A1 (en) * | 2014-02-21 | 2015-08-27 | Genmont Biotech Incorporation | Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases |
WO2017147561A1 (fr) * | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | Anticorps se liant aux hémicanaux de la connexine (cx) 43 et leurs utilisations |
CN107050011A (zh) * | 2017-04-28 | 2017-08-18 | 灏ゅ己 | 染料木素在制备抗自身免疫性肝炎药物中的应用 |
Non-Patent Citations (4)
Title |
---|
ABLASSER ET AL.: "Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP", NATURE, vol. 503, no. 7477, 2013, pages 530 - 534, XP055172189, DOI: 10.1038/nature12640 * |
ABLASSER ET AL.: "TREX1 Deficiency Triggers Cell -Autonomous Immunity in a cGAS-Dependent Manner", THE JOURNAL OF IMMUNOLOGY, vol. 192, 9 May 2014 (2014-05-09), pages 1 - 5, XP055654926 * |
NANKE ET AL.: "Experimental Immunology- Tumor necrosis factor-a and matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue is inhibited by blocking gap junction communication", CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 37, no. 3, 2012, pages 237 - 242, XP055654924 * |
WINKELMANN ET AL.: "Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria", JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY, vol. 6, no. 1, January 2013 (2013-01-01), pages 27 - 38, XP055654930 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220218798A9 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
Gotts et al. | Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy | |
EP3675650B1 (fr) | Compositions et méthodes de protection contre des agents pathogènes et irritants en suspension dans l'air | |
JP2023058599A (ja) | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 | |
JP2016128515A (ja) | 免疫関連障害の局所治療に使用するためのエアゾール化lfa−1アンタゴニスト | |
Tong et al. | Norisoboldine ameliorates collagen-induced arthritis through regulating the balance between Th17 and regulatory T cells in gut-associated lymphoid tissues | |
JP2017501975A (ja) | 認知症を予防及び/又は治療するための薬剤の調製におけるジンセノサイドRg3の適用、並びに認知症を治療する薬剤 | |
EP3302439A1 (fr) | Composition thérapeutique | |
WO2019046664A1 (fr) | Compositions et méthodes de protection contre des agents pathogènes et irritants | |
WO1999051223A1 (fr) | Ansamycines benzoquinoides pour le traitement d'une crise ou d'un arret cardiaque | |
US6653344B2 (en) | Pharmaceutical preparations containing a dibenzocyclooctane lignan derivative for treatment of neurodegenerative disease | |
WO2019222800A1 (fr) | Procédés pour le traitement ou la prévention de maladies auto-immunes ou auto-inflammatoires | |
KR101514257B1 (ko) | 의약 조성물 및 이를 이용한 약용 화장품 | |
KR101885591B1 (ko) | 휴매닌 또는 이의 유사체를 유효성분으로 함유하는 창상 치료용 약학적 조성물 | |
US20220047614A1 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
CN114366732B (zh) | 泰妙菌素在制备用于治疗银屑病的药物中的应用 | |
RU2790223C2 (ru) | Композиции и способы защиты от взвешенных в воздухе патогенов и раздражающих веществ | |
US20230391837A1 (en) | Methods of treating, ameliorating, and/or preventing covid-19 infection and related inflammation | |
CN109232704B (zh) | 黄花远志皂苷e、包含其的提取物及应用 | |
WO2020061874A1 (fr) | Application de ginsénoside ck dans la préparation d'un médicament oral pour le traitement du psoriasis vulgaire modéré à grave | |
WO2023167869A1 (fr) | Compositions et procédés de modulation de l'activité des lymphocytes t du facteur nucléaire des lymphocytes t activés (nfat) | |
JP2023525662A (ja) | トレハロース又はトレハロースの誘導体を含有する医薬及び経鼻スプレー | |
KR20230010886A (ko) | 무독성 황 또는 메틸설포닐메탄을 포함하는 피부염증 예방 또는 개선용 조성물 | |
KR101065020B1 (ko) | 캠퍼롤을 유효성분으로 포함하는 화상 치료용 조성물 | |
SE454402B (sv) | Nasalt administrerbar farmaceutisk komposition innehallande en ergotpeptidalkaloid samt ett xantin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19807308 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19807308 Country of ref document: EP Kind code of ref document: A1 |